NL-OMON55729已完成4 期
The noradrenergic basis of Parkinson*s tremor: a systems-level fMRI approach - Noradrenergic basis of Parkinson tremor
eurologie0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- idiopathic Parkinson*s disease according to UK Brain Bank criteriaPatients
- •will fall in one of two groups (Parkinson phenotypes); either:
- •- tremor-dominant phenotype (defined as a resting tremor score of ><= 2 UPDRS
- •points for at least one arm) or:
- •- non-tremor phenotype (defined as a resting tremore score of 0 points on the
排除标准
- •- use of beta-blockers
- •- neuropsychiatric co-morbidity
- •- contraindications for MRI scanning (e.g. pacemaker, implanted metal parts,
- •deep brain stimulation, claustrophobia)
- •- Cardiac arrhythmias (in patient history or visible on ECG)
- •- contraindications for beta blockers (e.g. bradycardia, peripheral circulation
- •disturbances, asthma or obstructive lung disease, hypotension)
- •- Use of medication that may interact with propranolol, e.g. other bèta-
- •blockers, calcium antagonists, digoxine, cimetidine, hydralazine, fluvoxamine,
- •rifampicine, barbiturates, amiodaron, flecainide, kinidine, propafenon,
- •disopyramide, chlorpromazine, and clonidine
- •- Use of medication that inhibits relevant CYP enzymes that are involved in
- •metabolizing propranolol (CYP2D6, CYP1A2, and CYP2C19): fluoxetine, paroxetine,
- •sertraline, duloxetine, terbinafine, cinacalcet, bupropion, and ciprofloxacine
- •- Severe head tremor or dyskinesias
- •- Cognitive impairment (MMSE < 26)
- •- Severe PD: disease duration > 10 years, severe ON/OFF fluctuations, or
- •levodopa equivalent dose >1200 mg
研究者
相似试验
已完成
2 期
The influence of stress on Parkinson's tremorParkinson's diseaseISRCTN89589002Radboud University Nijmegen64
进行中（未招募）
1 期
The influence of stress on Parkinson's tremorTremor in Parkinson's diseaseEUCTR2016-004629-18-NLRadboud University Nijmegen60
已完成
3 期
Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's DiseaseParkinson's DiseaseNCT01504178University Hospital, Toulouse28
Unknown
不适用
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced DyskinesiaParkinson´s DiseaseNCT02578849Aarhus University Hospital45
招募中
不适用
Pathophysiological analysis of Parkinson disease and related disorders using DAT scan and MRIParkinson disease and related disordersJPRN-UMIN000014389Department of Radiology, Juntendo University School of Medicine60